The DOI matches its Crossref record; 190 of the 190 references it cites were found in a registry or an index.
Recent Advances in the Treatment of Malignant Astrocytoma
Abstract
Malignant gliomas, including the most common subtype, glioblastoma multiforme (GBM), are among the most devastating of neoplasms. Their aggressive infiltration in the CNS typically produces progressive and profound disability—ultimately leading to death in nearly all cases. Improvement in outcome has been elusive despite decades of intensive clinical and laboratory research. Surgery and radiotherapy, the traditional cornerstones of therapy, provide palliative benefit, while the value of chemotherapy has been marginal and controversial. Limited delivery and tumor heterogeneity are two fundamental factors that have critically hindered therapeutic progress. A novel chemoradiotherapy approach, consisting of temozolomide administered concurrently during radiotherapy followed by adjuvant systemic temozolomide, has recently demonstrated a meaningful, albeit modest, improvement in overall survival for newly diagnosed GBM patients. As cell-signaling alterations linked to the development and progression of gliomas are being increasingly elucidated, targeted therapies have rapidly entered preclinical and clinical evaluation. Responses to therapies that function via DNA damage have been associated with specific mediators of resistance that may also be subject to targeted therapies. Other approaches include novel locoregional delivery techniques to overcome barriers of delivery. The simultaneous development of multiple advanced therapies based on specific tumor biology may finally offer glioma patients improved survival.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Radiotherapy Plus Concomitant and Adjuvant Temozolomide for Glioblastoma
Stupp, R., Mason, W. P., van den Bent, M. J., Weller, M., Fisher, B., Taphoorn, M. J. B., Belanger, K., Brandes, A. A., Marosi, C., Bogdahn, U., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa043330 · Cited by 21,807
Slamon, D. J., Leyland-Jones, B., Shak, S., Fuchs, H., Paton, V., Bajamonde, A., Fleming, T., Eiermann, W., Wolter, J., Pegram, M., et al. (2001) · New England Journal of Medicine · doi:10.1056/nejm200103153441101 · Cited by 11,500 · cited 1×
“colorectal cancer),(183) erlotinib (epidermal growth factor receptorinhibitor for lung cancer),(184) and trastuzumab (Her-2-neu monoclonal antibody for breast cancer).(185) The role of molecular targeted agents for malignant glioma patients remains to be determined.”
BackgroundLynch, T. J., Bell, D. W., Sordella, R., Gurubhagavatula, S., Okimoto, R. A., Brannigan, B. W., Harris, P. L., Haserlat, S. M., Supko, J. G., Haluska, F. G., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa040938 · Cited by 11,486
Bevacizumab plus Irinotecan, Fluorouracil, and Leucovorin for Metastatic Colorectal Cancer
Hurwitz, H., Fehrenbacher, L., Novotny, W., Cartwright, T., Hainsworth, J., Heim, W., Berlin, J., Baron, A., Griffing, S., Holmgren, E., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa032691 · Cited by 10,968
EGFR Mutations in Lung Cancer: Correlation with Clinical Response to Gefitinib Therapy
Paez, J. G., Jänne, P. A., Lee, J. C., Tracy, S., Greulich, H., Gabriel, S., Herman, P., Kaye, F. J., Lindeman, N., Boggon, T. J., et al. (2004) · Science · doi:10.1126/science.1099314 · Cited by 9,368
MGMT Gene Silencing and Benefit from Temozolomide in Glioblastoma
Hegi, M. E., Diserens, A.-C., Gorlia, T., Hamou, M.-F., de Tribolet, N., Weller, M., Kros, J. M., Hainfellner, J. A., Mason, W., Mariani, L., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa043331 · Cited by 7,405
World Health Organization Classification of Tumours
Fletcher, C., van den Berg, A., & Molenaar, I. (2002) · Cited by 7,079
The phosphatidylinositol 3-Kinase–AKT pathway in human cancer
Vivanco, I., & Sawyers, C. L. (2002) · Nature Reviews Cancer · doi:10.1038/nrc839 · Cited by 6,056
Methylation-specific PCR: a novel PCR assay for methylation status of CpG islands.
Herman, J. G., Graff, J. R., Myöhänen, S., Nelkin, B. D., & Baylin, S. B. (1996) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.93.18.9821 · Cited by 5,646
Erlotinib in Previously Treated Non–Small-Cell Lung Cancer
Shepherd, F. A., Rodrigues Pereira, J., Ciuleanu, T., Tan, E. H., Hirsh, V., Thongprasert, S., Campos, D., Maoleekoonpiroj, S., Smylie, M., Martins, R., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa050753 · Cited by 5,419
Druker, B. J., Talpaz, M., Resta, D. J., Peng, B., Buchdunger, E., Ford, J. M., Lydon, N. B., Kantarjian, H., Capdeville, R., Ohno-Jones, S., et al. (2001) · New England Journal of Medicine · doi:10.1056/nejm200104053441401 · Cited by 5,243
Li, J., Yen, C., Liaw, D., Podsypanina, K., Bose, S., Wang, S. I., Puc, J., Miliaresis, C., Rodgers, L., McCombie, R., et al. (1997) · Science · doi:10.1126/science.275.5308.1943 · Cited by 4,785
Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors
Demetri, G. D., von Mehren, M., Blanke, C. D., Van den Abbeele, A. D., Eisenberg, B., Roberts, P. J., Heinrich, M. C., Tuveson, D. A., Singer, S., Janicek, M., et al. (2002) · New England Journal of Medicine · doi:10.1056/nejmoa020461 · Cited by 4,389
Pao, W., Miller, V., Zakowski, M., Doherty, J., Politi, K., Sarkaria, I., Singh, B., Heelan, R., Rusch, V., Fulton, L., et al. (2004) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0405220101 · Cited by 4,338
Estimating the world cancer burden: Globocan 2000
Parkin, D. M., Bray, F., Ferlay, J., & Pisani, P. (2001) · International Journal of Cancer · doi:10.1002/ijc.1440 · Cited by 3,721
Tumour stem cells and drug resistance
Dean, M., Fojo, T., & Bates, S. (2005) · Nature reviews. Cancer · doi:10.1038/nrc1590 · Cited by 3,668
Steck, P. A., Pershouse, M. A., Jasser, S. A., Yung, W. K. A., Lin, H., Ligon, A. H., Langford, L. A., Baumgard, M. L., Hattier, T., Davis, T., et al. (1997) · Nature Genetics · doi:10.1038/ng0497-356 · Cited by 2,741
Isolation and Characterization of Tumorigenic, Stem-like Neural Precursors from Human Glioblastoma
Galli, R., Binda, E., Orfanelli, U., Cipelletti, B., Gritti, A., De Vitis, S., Fiocco, R., Foroni, C., Dimeco, F., & Vescovi, A. (2004) · Cancer Research · doi:10.1158/0008-5472.can-04-1364 · Cited by 2,570
Negative regulation of PKB/Akt-dependent cell survival by the tumor suppressor PTEN
Stambolic, V., Suzuki, A., de la Pompa, J. L., Brothers, G. M., Mirtsos, C., Sasaki, T., Ruland, J., Penninger, J. M., Siderovski, D. P., & Mak, T. W. (1998) · Cell · doi:10.1016/s0092-8674(00)81780-8 · Cited by 2,551
World Health Organization classification of tumors
Kleihues, P., & Sobin, L. H. (2000) · Cancer · doi:10.1002/1097-0142(20000615)88:12<2887::aid-cncr32>3.0.co;2-f · Cited by 2,377
Inactivation of the DNA-Repair Gene MGMT and the Clinical Response of Gliomas to Alkylating Agents
Esteller, M., Garcia-Foncillas, J., Andion, E., Goodman, S. N., Hidalgo, O. F., Vanaclocha, V., Baylin, S. B., & Herman, J. G. (2000) · New England Journal of Medicine · doi:10.1056/nejm200011093431901 · Cited by 2,224
High Interstitial Fluid Pressure - an Obstacle in Cancer Therapy
Heldin, C.-H., Rubin, K., Pietras, K., & Östman, A. (2004) · Nature reviews. Cancer · doi:10.1038/nrc1456 · Cited by 2,222
Walker, M. D., Alexander, E., Hunt, W. E., MacCarty, C. S., Mahaley, M. S., Mealey, J., Norrell, H. A., Owens, G., Ransohoff, J., Wilson, C. B., et al. (1978) · Journal of Neurosurgery · doi:10.3171/jns.1978.49.3.0333 · Cited by 1,667
Cairncross, J. G., Ueki, K., Zlatescu, M. C., Lisle, D. K., Finkelstein, D. M., Hammond, R. R., Silver, J. S., Stark, P. C., Macdonald, D. R., Ino, Y., et al. (1998) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/90.19.1473 · Cited by 1,610
Libermann, T. A., Nusbaum, H. R., Razon, N., Kris, R., Lax, I., Soreq, H., Whittle, N., Waterfield, M. D., Ullrich, A., & Schlessinger, J. (1985) · Nature · doi:10.1038/313144a0 · Cited by 1,503
Convection-enhanced delivery of macromolecules in the brain.
Bobo, R. H., Laske, D. W., Akbasak, A., Morrison, P. F., Dedrick, R. L., & Oldfield, E. H. (1994) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.91.6.2076 · Cited by 1,415
Brem, H., Piantadosi, S., Burger, P. C., Walker, M., Selker, R., Vick, N. A., Black, K., Sisti, M., Brem, S., Mohr, G., et al. (1995) · The Lancet · doi:10.1016/s0140-6736(95)90755-6 · Cited by 1,389
Tyrosine Kinases as Targets for Cancer Therapy
Krause, D. S., & Van Etten, R. A. (2005) · New England Journal of Medicine · doi:10.1056/nejmra044389 · Cited by 1,387
Westphal, M., Hilt, D. C., Bortey, E., Delavault, P., Olivares, R., Warnke, P. C., Whittle, I. R., Jääskeläinen, J., & Ram, Z. (2003) · Neuro-Oncology · doi:10.1093/neuonc/5.2.79 · Cited by 1,330
Curran, W. J., Scott, C. B., Horton, J., Nelson, J. S., Weinstein, A. S., Fischbach, A. J., Chang, C. H., Rotman, M., Asbell, S. O., Krisch, R. E., et al. (1993) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/85.9.704 · Cited by 1,310
Genetic Pathways to Glioblastoma
Ohgaki, H., Dessen, P., Jourde, B., Horstmann, S., Nishikawa, T., Di Patre, P.-L., Burkhard, C., Schüler, D., Probst-Hensch, N. M., Maiorka, P. C., et al. (2004) · Cancer Research · doi:10.1158/0008-5472.can-04-1337 · Cited by 1,270
Neural Stem Cells and the Origin of Gliomas
Sanai, N., Alvarez-Buylla, A., & Berger, M. S. (2005) · New England Journal of Medicine · doi:10.1056/nejmra043666 · Cited by 1,044
Assumptions in the radiotherapy of glioblastoma
Hochberg, F. H., & Pruitt, A. (1980) · Neurology · doi:10.1212/wnl.30.9.907 · Cited by 992
P-Glycoprotein, a gatekeeper in the blood–brain barrier
Schinkel, A. H. (1999) · Advanced Drug Delivery Reviews · doi:10.1016/s0169-409x(98)00085-4 · Cited by 960
Nutt, C. L., Mani, D. R., Betensky, R. A., Tamayo, P., Cairncross, J. G., Ladd, C., Pohl, U., Hartmann, C. J., McLaughlin, M. E., Batchelor, T. T., et al. (2003) · PubMed · Cited by 959
Yung, W. K. A., Albright, R. E., Olson, J., Fredericks, R., Fink, K., Prados, M. D., Brada, M., Spence, A., Hohl, R. J., Shapiro, W., et al. (2000) · British Journal of Cancer · doi:10.1054/bjoc.2000.1316 · Cited by 929
Self-citationFine, H. A., Dear, K. B. G., Loeffler, J. S., Mc Black, P. L., & Canellos, G. P. (1993) · Cancer · doi:10.1002/1097-0142(19930415)71:8<2585::aid-cncr2820710825>3.0.co;2-s · Cited by 864
Stupp, R., Dietrich, P.-Y., Ostermann, S., Pica, A., Maillard, I. P., Maeder, P., Meuli, R. A., Janzer, R. C., Pizzolato, G., Miralbell, R., et al. (2002) · Journal of Clinical Oncology · doi:10.1200/jco.20.5.1375 · Cited by 856
An analysis of dose-effect relationship in the radiotherapy of malignant gliomas
Walker, M. D., Strike, T. A., & Sheline, G. E. (1979) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/0360-3016(79)90553-4 · Cited by 854
Wong, A. J., Bigner, S. H., Bigner, D. D., Kinzler, K. W., Hamilton, S. R., & Vogelstein, B. (1987) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.84.19.6899 · Cited by 849
Self-citationEpidemiology of primary brain tumors: Current concepts and review of the literature
Wrensch, M., Minn, Y., Chew, T., Bondy, M., & Berger, M. S. (2002) · Neuro-Oncology · doi:10.1093/neuonc/4.4.278 · Cited by 837
Newlands, E. S., Stevens, M. F. G., Wedge, S. R., Wheelhouse, R. T., & Brock, C. (1997) · Cancer Treatment Reviews · doi:10.1016/s0305-7372(97)90019-0 · Cited by 817
MGMT: its role in cancer aetiology and cancer therapeutics
Gerson, S. L. (2004) · Nature Reviews Cancer · doi:10.1038/nrc1319 · Cited by 813
Hegi, M. E., Diserens, A.-C., Godard, S., Dietrich, P.-Y., Regli, L., Ostermann, S., Otten, P., Van Melle, G., de Tribolet, N., & Stupp, R. (2004) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-03-0384 · Cited by 783
Delivery of molecular and cellular medicine to solid tumors
Jain, R. K. (2012) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2012.09.011 · Cited by 774
Yung, W. K. A., Prados, M. D., Yaya-Tur, R., Rosenfeld, S. S., Brada, M., Friedman, H. S., Albright, R., Olson, J., Chang, S. M., O'Neill, A. M., et al. (1999) · Journal of Clinical Oncology · doi:10.1200/jco.1999.17.9.2762 · Cited by 761
Self-citationGene Expression Profiling of Gliomas Strongly Predicts Survival
Freije, W. A., Castro-Vargas, F. E., Fang, Z., Horvath, S., Cloughesy, T., Liau, L. M., Mischel, P. S., & Nelson, S. F. (2004) · Cancer Research · doi:10.1158/0008-5472.can-04-0452 · Cited by 744
Diversity and frequency of epidermal growth factor receptor mutations in human glioblastomas.
Frederick, L. A., Wang, X. Y., Eley, G. D., & James, C. D. (2000) · PubMed · Cited by 740
Phase II Trial of Gefitinib in Recurrent Glioblastoma
Rich, J. N., Reardon, D. A., Peery, T., Dowell, J. M., Quinn, J. A., Penne, K. L., Wikstrand, C. J., Van Duyn, L. B., Dancey, J. E., McLendon, R. E., et al. (2004) · Journal of Clinical Oncology · doi:10.1200/jco.2004.08.110 · Cited by 734
Self-citationTemozolomide and treatment of malignant glioma
Friedman, H. S., Kerby, T., & Calvert, H. (2000) · PubMed · doi:10.25405/ncl.34644405 · Cited by 731
Self-citationCritical Update and Emerging Trends in Epidermal Growth Factor Receptor Targeting in Cancer
Baselga, J., & Arteaga, C. L. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.11.890 · Cited by 725
Ekstrand, A. J., James, C. D., Cavenee, W. K., Seliger, B., Pettersson, R. F., & Collins, V. P. (1991) · PubMed · Cited by 719
Hermanson, M., Funa, N. S., Hartman, M., Claesson, L., Heldin, C., Westermark, B., & Nistér, M. (1992) · PubMed · Cited by 705
Galanis, E., Buckner, J. C., Maurer, M. J., Kreisberg, J. I., Ballman, K., Boni, J., Peralba, J. M., Jenkins, R. B., Dakhil, S. R., Morton, R. F., et al. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.23.622 · Cited by 694
Wu, X., Senechal, K., Neshat, M. S., Whang, Y. E., & Sawyers, C. L. (1998) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.95.26.15587 · Cited by 674
Clonal expansion of p53 mutant cells is associated with brain tumour progression
Sidransky, D., Mikkelsen, T., Schwechheimer, K., Rosenblum, M. L., Cavanee, W., & Vogelstein, B. (1992) · Nature · doi:10.1038/355846a0 · Cited by 670
Glioblastoma multiforme and anaplastic astrocytoma pathologic criteria and prognostic implications
Burger, P. C., Vogel, F. S., Green, S. B., & Strike, T. A. (1985) · Cancer · doi:10.1002/1097-0142(19850901)56:5<1106::aid-cncr2820560525>3.0.co;2-2 · Cited by 651
Huang, H.-J. S., Nagane, M., Klingbeil, C. K., Lin, H., Nishikawa, R., Ji, X.-D., Huang, C.-M., Gill, G. N., Wiley, H. S., & Cavenee, W. K. (1997) · Journal of Biological Chemistry · doi:10.1074/jbc.272.5.2927 · Cited by 595
Sugawa, N., Ekstrand, A. J., James, C. D., & Collins, V. P. (1990) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.87.21.8602 · Cited by 594
Cancer stem cells in nervous system tumors
Singh, S. K., Clarke, I. D., Hide, T., & Dirks, P. B. (2004) · Oncogene · doi:10.1038/sj.onc.1207946 · Cited by 569
Souhami, L., Seiferheld, W., Brachman, D., Podgorsak, E. B., Werner-Wasik, M., Lustig, R., Schultz, C. J., Sause, W., Okunieff, P., Buckner, J., et al. (2004) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/j.ijrobp.2004.04.011 · Cited by 562
Reifenberger, G., Liu, L., Ichimura, K., Schmidt, E., & Collins, V. P. (1993) · PubMed · Cited by 560
Simpson, J. R., Horton, J., Scott, C., Curran, W. J., Rubin, P., Fischbach, J., Isaacson, S., Rotman, M., Asbell, S. O., Nelson, J. S., et al. (1993) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/0360-3016(93)90203-8 · Cited by 535
Jain, R. K. (2001) · Advanced Drug Delivery Reviews · doi:10.1016/s0169-409x(00)00131-9 · Cited by 529
Laske, D. W., Youle, R. J., & Oldfield, E. H. (1997) · Nature Medicine · doi:10.1038/nm1297-1362 · Cited by 525
Ostermann, S., Csajka, C., Buclin, T., Leyvraz, S., Lejeune, F., Decosterd, L. A., & Stupp, R. (2004) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-03-0807 · Cited by 518
CDKN2 (p16/MTS1) gene deletion or CDK4 amplification occurs in the majority of glioblastomas.
Schmidt, E., Ichimura, K., Reifenberger, G., & Collins, V. P. (1994) · PubMed · Cited by 508
Epidermal growth factor receptor, protein kinase B/Akt, and glioma response to erlotinib
Haas-Kogan, D. A., Prados, M. D., Tihan, T., Eberhard, D. A., Jelluma, N., Arvold, N. D., Baumber, R., Lamborn, K. R., Kapadia, A., Malec, M., et al. (2005) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/dji161 · Cited by 465
The blood-brain and blood-tumor barriers: A review of strategies for increasing drug delivery
Groothuis, D. R. (2000) · Neuro-Oncology · doi:10.1093/neuonc/2.1.45 · Cited by 456
Denny, B. J., Wheelhouse, R. T., Stevens, M. F. G., Tsang, L. L. H., & Slack, J. A. (1994) · Biochemistry · doi:10.1021/bi00197a003 · Cited by 442
Friedman, H. S., McLendon, R. E., Kerby, T., Dugan, M., Bigner, S. H., Henry, A. J., Ashley, D. M., Krischer, J., Lovell, S., Rasheed, K., et al. (1998) · Journal of Clinical Oncology · doi:10.1200/jco.1998.16.12.3851 · Cited by 423
Self-citationDeletion of p16 and p15 genes in brain tumors.
Jen, J., Harper, J. W., Bigner, S. H., Bigner, D. D., Papadopoulos, N., Markowitz, S. D., Willson, J. K. V., Kinzler, K. W., & Vogelstein, B. (1994) · PubMed · Cited by 404
Self-citationCDKN2/p16 or RB alterations occur in the majority of glioblastomas and are inversely correlated.
Ueki, K., Ono, Y., Henson, J. W., Efird, J. T., von Deimling, A., & Louis, D. N. (1996) · PubMed · Cited by 404
Phase II study of CCI-779 in patients with recurrent glioblastoma multiforme
Chang, S. M., Wen, P., Cloughesy, T., Greenberg, H., Schiff, D., Conrad, C., Fink, K., Robins, H. I., De Angelis, L., Raizer, J., et al. (2005) · Investigational New Drugs · doi:10.1007/s10637-005-1444-0 · Cited by 395
Chinnaiyan, P., Huang, S., Vallabhaneni, G., Armstrong, E., Varambally, S., Tomlins, S. A., Chinnaiyan, A. M., & Harari, P. M. (2005) · Cancer Research · doi:10.1158/0008-5472.can-04-3547 · Cited by 386
(1992) · PubMed · Cited by 383
The prognostic significance of phosphatidylinositol 3-kinase pathway activation in human gliomas
Chakravarti, A., Zhai, G., Suzuki, Y., Sarkesh, S., Black, P. M., Muzikansky, A., & Loeffler, J. S. (2004) · Journal of Clinical Oncology · doi:10.1200/jco.2004.07.193 · Cited by 377
Capillary Ultrastructure and the Blood-Brain Barrier in Human Malignant Brain Tumors
Long, D. M. (1970) · Journal of Neurosurgery · doi:10.3171/jns.1970.32.2.0127 · Cited by 371
Tolcher, A. W., Gerson, S. L., Denis, L., Geyer, C., Hammond, L. A., Patnaik, A., Goetz, A. D., Schwartz, G., Edwards, T., Reyderman, L., et al. (2003) · British Journal of Cancer · doi:10.1038/sj.bjc.6600827 · Cited by 368
Hypoxia Is Important in the Biology and Aggression of Human Glial Brain Tumors
Evans, S. M., Judy, K. D., Dunphy, I., Jenkins, W. T., Hwang, W.-T., Nelson, P. T., Lustig, R. A., Jenkins, K., Magarelli, D. P., Hahn, S. M., et al. (2004) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-04-1081 · Cited by 356
Germ-line p53 mutations predispose to a wide spectrum of early-onset cancers.
Nichols, K. E., Malkin, D. M., Garber, J. E., Fraumeni, J. F., & Li, F. P. (2001) · PubMed · Cited by 354
Nistér, M., Libermann, T. A., Betsholtz, C., Pettersson, M., Claesson, L., Heldin, C., Schlessinger, J., & Westermark, B. (1988) · PubMed · Cited by 353
Rickman, D. S., Bobek, M. P., Misek, D. E., Kuick, R. D., Blaivas, M., Kurnit, D. M., Taylor, J. M. G., & Hanash, S. (2001) · PubMed · Cited by 352
Breedveld, P., Pluim, D., Cipriani, G., Wielinga, P., van Tellingen, O., Schinkel, A. H., & Schellens, J. H. M. (2005) · Cancer Research · doi:10.1158/0008-5472.can-04-2416 · Cited by 351
Lidar, Z., Mardor, Y., Jonas, T., Pfeffer, R., Faibel, M., Nass, D., Hadani, M., & Ram, Z. (2004) · Journal of Neurosurgery · doi:10.3171/jns.2004.100.3.0472 · Cited by 342
Angiogenesis in malignant gliomas
Plate, K. H., & Risau, W. (1995) · Glia · doi:10.1002/glia.440150313 · Cited by 337
Geng, L., Donnelly, E. F., McMahon, G., Lin, P. C., Sierra‐Rivera, E., Oshinka, H., & Hallahan, D. E. (2001) · PubMed · Cited by 334
Ichimura, K., Bondesson, M., Goike, H., Schmidt, E., Moshref, A., & Collins, V. P. (2000) · PubMed · Cited by 333
Reardon, D. A., Egorin, M. J., Quinn, J. A., Rich, J. N., Gururangan, I., Vredenburgh, J. J., Desjardins, A., Sathornsumetee, S., Provenzale, J. M., Herndon, J. E., et al. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.03.2185 · Cited by 330
Self-citationGene expression profiling identifies molecular subtypes of gliomas
Shai, R., Shi, T., Kremen, T. J., Horvath, S., Liau, L. M., Cloughesy, T. F., Mischel, P. S., & Nelson, S. F. (2003) · Oncogene · doi:10.1038/sj.onc.1206753 · Cited by 328
By the Medical Research Council Brain Tumour Working Party (2001) · Journal of Clinical Oncology · doi:10.1200/jco.2001.19.2.509 · Cited by 325
Houghton, P. J., Germain, G. S., Harwood, F. C., Schuetz, J. D., Stewart, C. F., Buchdunger, E., & Traxler, P. (2004) · Cancer Research · doi:10.1158/0008-5472.can-03-3344 · Cited by 323
Scott Ph.D., C. B., Scarantino M.D., P. D., Urtasun M.D., Movsas M.D., Jones M.D., Simpson M.D., Fischbach M.D., & Curran Jr., M. D. (1998) · International Journal of Radiation OncologyBiologyPhysics · doi:10.1016/s0360-3016(97)00485-9 · Cited by 323
Godard, S., Getz, G. A., Delorenzi, M., Farmer, P. J., Kobayashi, H., Desbaillets, I., Nozaki, M., Diserens, A., Hamou, M., Dietrich, P., et al. (2003) · PubMed · Cited by 319
Gene expression profiling and genetic markers in glioblastoma survival
Rich, J. N., Hans, C., Jones, B., Iversen, E. S., McLendon, R. E., Rasheed, B. K. A., Dobra, A., Dressman, H. K., Bigner, D. D., Nevins, J. R., et al. (2005) · Cancer Research · doi:10.1158/0008-5472.can-04-3936 · Cited by 316
Self-citationSomatic Mutations of EGFR in Colorectal Cancers and Glioblastomas
Barber, T. D., Vogelstein, B., Kinzler, K. W., & Velculescu, V. E. (2004) · New England Journal of Medicine · doi:10.1056/nejm200412303512724 · Cited by 315
Mechanisms of Disease: The Blood-Brain Barrier
Neuwelt, E. A. (2004) · Neurosurgery · doi:10.1227/01.neu.0000097715.11966.8e · Cited by 314
Transferrin Receptor Ligand-Targeted Toxin Conjugate (Tf-CRM107) for Therapy of Malignant Gliomas
Weaver, M., & Laske, D. W. (2003) · Journal of Neuro-Oncology · doi:10.1023/a:1026246500788 · Cited by 299
Jaeckle, K. A., Eyre, H. J., Townsend, J. J., Schulman, S., Knudson, H. M., Belanich, M., Yarosh, D. B., Bearman, S. I., Giroux, D. J., & Schold, S. C. (1998) · Journal of Clinical Oncology · doi:10.1200/jco.1998.16.10.3310 · Cited by 297
Guha, A. R., Dashner, K., Black, P. L. M., et al. (1995) · International Journal of Cancer · doi:10.1002/ijc.2910600206 · Cited by 296
Gaspar, L. E., Fisher, B. J., Macdonald, D. R., Leber, D. V., Halperin, E. C., Schold, S. C., & Cairncross, J. G. (1992) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/0360-3016(92)91021-e · Cited by 295
p53 mutations are associated with 17p allelic loss in grade II and grade III astrocytoma.
von Deimling, A., Eibl, R. H., Ohgaki, H., Louis, D. N., von Ammon, K., Petersen, I., Kleihues, P., Chung, R. Y., Wiestler, O., & Seizinger, B. R. (1992) · PubMed · Cited by 291
Quinn, J. A., Desjardins, A., Weingart, J., Brem, H., Dolan, M. E., Delaney, S. M., Vredenburgh, J., Rich, J., Friedman, A. H., Reardon, D. A., et al. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.06.502 · Cited by 288
Self-citationPhase I trial of temozolomide using an extended continuous oral schedule.
Brock, C., Newlands, E. S., Wedge, S. R., Bower, M., Evans, H. S., Colquhoun, I. R., Roddie, M., Glaser, M. G., Brampton, M., & Rustin, G. J. S. (1998) · PubMed · Cited by 284
Humphrey, P. A., Wong, A. J., Vogelstein, B., Friedman, H. S., Werner, M. H., Bigner, D. D., & Bigner, S. H. (1988) · PubMed · Cited by 275
Self-citationDistribution of STI-571 to the Brain Is Limited by P-Glycoprotein-Mediated Efflux
Dai, H., Marbach, P., Lemaire, M., Hayes, M., & Elmquist, W. F. (2003) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.102.045260 · Cited by 273
Athanassiou, H., Synodinou, M., Maragoudakis, E., Paraskevaidis, M., Verigos, C., Misailidou, D., Antonadou, D., Saris, G., Beroukas, K., & Karageorgis, P. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.00.331 · Cited by 272
Identification of molecular subtypes of glioblastoma by gene expression profiling
Mischel, P. S., Shai, R., Shi, T., Horvath, S., Lu, K. V., Choe, G., Seligson, D., Kremen, T. J., Palotie, A., Liau, L. M., et al. (2003) · Oncogene · doi:10.1038/sj.onc.1206344 · Cited by 272
Adult glioma incidence trends in the United States, 1977–2000
Hess, K. R., Broglio, K. R., & Bondy, M. L. (2004) · Cancer · doi:10.1002/cncr.20621 · Cited by 270
Selker, R. G., Shapiro, W. R., Burger, P., Blackwood, M. S., Deutsch, M., Arena, V. C., Van Gilder, J. C., Wu, J., Malkin, M. G., Mealey, J., et al. (2002) · Neurosurgery · doi:10.1097/00006123-200208000-00009 · Cited by 260
(1999) · PubMed · Cited by 258
Hermanson, M., Funa, K., Koopmann, J., Maintz, D. C., Waha, A., Westermark, B., Heldin, C. H., Wiestler, O. D., Louis, D. N., von Deimling, A., et al. (1996) · PubMed · Cited by 255
Reardon, D. A. (2002) · Journal of Clinical Oncology · doi:10.1200/jco.20.5.1389 · Cited by 255
Self-citationCurrent and future developments in the use of temozolomide for the treatment of brain tumours
Stupp, R., Gander, M., Leyvraz, S., & Newlands, E. (2001) · The Lancet Oncology · doi:10.1016/s1470-2045(01)00489-2 · Cited by 254
Imaging‐guided convection‐enhanced delivery and gene therapy of glioblastoma
Voges, J., Reszka, R., Gossmann, A., Dittmar, C., Richter, R., Garlip, G., Kracht, L., Coenen, H. H., Sturm, V., Wienhard, K., et al. (2003) · Annals of Neurology · doi:10.1002/ana.10688 · Cited by 250
Development of novel targeted therapies in the treatment of malignant glioma
Rich, J. N., & Bigner, D. D. (2004) · Nature Reviews Drug Discovery · doi:10.1038/nrd1380 · Cited by 247
Self-citationVascular structures in brain tumors
Hirano, A., & Matsui, T. (1975) · Human Pathology · doi:10.1016/s0046-8177(75)80045-1 · Cited by 246
Belanich, M., Pastor, M., Randall, T., Guerra, D., Kibitel, J. T., Alas, L., Li, B., Citron, M. L., Wasserman, P., White, A., et al. (1996) · PubMed · Cited by 244
(1994) · PubMed · Cited by 244
Goudar, R. K., Shi, Q., Hjelmeland, M. D., Keir, S. T., McLendon, R. E., Wikstrand, C. J., Reese, E. D., Conrad, C. A., Traxler, P., Lane, H. A., et al. (2005) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.101.4.1 · Cited by 243
Self-citationSampson, J. H., Akabani, G., Archer, G. E., Bigner, D. D., Berger, M. S., Friedman, A. H., Friedman, H. S., Herndon II, J. E., Kunwar, S., Marcus, S., et al. (2003) · Journal of Neuro-Oncology · doi:10.1023/a:1026290315809 · Cited by 239
Self-citationIntracellular Signal Transduction Pathway Proteins As Targets for Cancer Therapy
Adjei, A. A., & Hidalgo, M. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.23.648 · Cited by 238
p14ARF Deletion and Methylation in Genetic Pathways to Glioblastomas
Nakamura, M., Watanabe, T., Klangby, U., Asker, C., Wiman, K., Yonekawa, Y., Kleihues, P., & Ohgaki, H. (2001) · Brain Pathology · doi:10.1111/j.1750-3639.2001.tb00388.x · Cited by 237
Chakravarti, A., Chakladar, A., Delaney, M. A., Latham, D. E., & Loeffler, J. S. (2002) · PubMed · Cited by 234
Rand, R. W., Kreitman, R. J., Patronas, N., Varricchio, F. E., Pastan, I. H., & Puri, R. K. (2000) · PubMed · Cited by 222
Antibody-guided three-step therapy for high grade glioma with yttrium-90 biotin
Paganelli, G., Grana, C., Chinol, M., Cremonesi, M., Cicco, C. D., de Braud, F., Robertson, C., Zurrida, S., Casadio, C., Zoboli, S., et al. (1999) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s002590050397 · Cited by 218
Wrensch, M., Lee, M., Miike, R., Newman, B., Bargar, G., Davis, R., Wiencke, J., & Neuhaus, J. (1997) · American Journal of Epidemiology · doi:10.1093/oxfordjournals.aje.a009154 · Cited by 218
Qian, X. C., & Brent, T. P. (1997) · PubMed · Cited by 214
Watts, G. S., Pieper, R. O., Costello, J. F., Peng, Y.-M., Dalton, W. S., & Futscher, B. W. (1997) · Molecular and Cellular Biology · doi:10.1128/mcb.17.9.5612 · Cited by 214
Weber, F., Asher, A., Bucholz, R., Berger, M., Prados, M., Chang, S., Bruce, J., Hall, W., Rainov, N. G., Westphal, M., et al. (2003) · Journal of Neuro-oncology · doi:10.1007/bf02700027 · Cited by 205
Mardor, Y., Roth, Y., Lidar, Z., Jonas, T., Pfeffer, R., Maier, S. E., Faibel, M., Nass, D., Hadani, M., Orenstein, A., et al. (2001) · PubMed · Cited by 204
Reardon, D. A., Akabani, G., Coleman, R. E., Friedman, A. H., Friedman, H. S., Herndon, J. E., McLendon, R. E., Pegram, C. N., Provenzale, J. M., Quinn, J. A., et al. (2006) · Journal of Clinical Oncology · doi:10.1200/jco.2005.03.4082 · Cited by 197
Self-citationBaker, C. H., Solórzano, C. C., & Fidler, I. J. (2002) · PubMed · Cited by 196
Bigner, D. D., Brown, M. T., Friedman, A. H., Coleman, R. E., Akabani, G., Friedman, H. S., Thorstad, W. L., McLendon, R. E., Bigner, S. H., Zhao, X. G., et al. (1998) · Journal of Clinical Oncology · doi:10.1200/jco.1998.16.6.2202 · Cited by 192
Self-citationHe, J., Olson, J. J., & James, C. D. (1995) · PubMed · Cited by 188
Brell, M., Tortosa, A., Verger, E., Gil, J. M., Viñolas, N., Villá, S., Acebes, J. J., Caral, L., Pujol, T., Ferrer, I., et al. (2005) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-05-0230 · Cited by 182
Amplification and Overexpression of MDM2 in Primary (de novo) Glioblastomas
BIERNAT, W., KLEIHUES, P., YONEKAWA, Y., & OHGAKI, H. (1997) · Journal of Neuropathology and Experimental Neurology · doi:10.1097/00005072-199702000-00009 · Cited by 178
Grana, C., Chinol, M., Robertson, C., Mazzetta, C., Bartolomei, M., De Cicco, C., Fiorenza, M., Gatti, M., Caliceti, P., & Paganelli, G. (2002) · British Journal of Cancer · doi:10.1038/sj.bjc.6600047 · Cited by 168
Vascular Microenvironment in Gliomas
Vajkoczy, P., & Menger, M. D. (2000) · Journal of Neuro-Oncology · doi:10.1023/a:1006474832189 · Cited by 167
Chang, S. M., Kuhn, J. G., Rizzo, J., Robins, H. I., Schold, S. C., Spence, A. M., Berger, M. S., Mehta, M. P., Bozik, M. E., Pollack, I., et al. (1998) · Journal of Clinical Oncology · doi:10.1200/jco.1998.16.6.2188 · Cited by 166
Molecular Classification and Survival Prediction in Human Gliomas Based on Proteome Analysis
Iwadate, Y., Sakaida, T., Hiwasa, T., Nagai, Y., Ishikura, H., Takiguchi, M., & Yamaura, A. (2004) · Cancer Research · doi:10.1158/0008-5472.can-03-1254 · Cited by 164
Fritz, G., Tano, K., MITRA, S. P., & Kaina, B. (1991) · Molecular and Cellular Biology · doi:10.1128/mcb.11.9.4660-4668.1991 · Cited by 160
Joensuu, H., Puputti, M., Sihto, H., Tynninen, O., & Nupponen, N. N. (2005) · The Journal of Pathology · doi:10.1002/path.1823 · Cited by 158
Kunwar, S. (2003) · Local Therapies for Glioma Present Status and Future Developments · doi:10.1007/978-3-7091-6090-9_16 · Cited by 158
Recent Advances in Brain Tumor Therapy: Local Intracerebral Drug Delivery by Polymers
Guérin, C. J., Olivi, A., WEINGART, J. D., Lawson, H. C., & Brem, H. (2003) · Investigational New Drugs · doi:10.1023/b:drug.0000006172.65135.3e · Cited by 153
Zalutsky, M. R., Moseley, R. P., Coakham, H. B., Coleman, R. E., & Bigner, D. D. (1989) · PubMed · Cited by 151
Self-citationFulci, G., Labuhn, M., Maier, D., Lachat, Y., Hausmann, O., Hegi, M. E., Janzer, R. C., Merlo, A., & Van Meir, E. G. (2000) · Oncogene · doi:10.1038/sj.onc.1203700 · Cited by 146
Survival of human glioma cells treated with various combination of temozolomide and X-rays
Rijn, J. V., Heimans, J. J., van den Berg, J., van der Valk, P., & Slotman, B. J. (2000) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/s0360-3016(99)00539-8 · Cited by 145
In vitro evaluation of temozolomide combined with X-irradiation
Wedge, S. R., Porteous, J. K., Glaser, M. G., Marcus, K., & Newlands, E. S. (1997) · Anti-Cancer Drugs · doi:10.1097/00001813-199701000-00013 · Cited by 145
Silber, J. R., Bobola, M. S., Ghatan, S., Blank, A., Kolstoe, D. D., & Berger, M. S. (1998) · PubMed · Cited by 144
Brem, H., Tamargo, R. J., Olivi, A., Pinn, M. L., WEINGART, J. D., Wharam, M. D., & Epstein, J. I. (1994) · Journal of neurosurgery · doi:10.3171/jns.1994.80.2.0283 · Cited by 144
Cokgor, I., Akabani, G., Kuan, C., Friedman, H. S., Friedman, A. H., Coleman, R. E., McLendon, R. E., Bigner, S. H., Zhao, X.-G., Garcia-Turner, A. M., et al. (2000) · Journal of Clinical Oncology · doi:10.1200/jco.2000.18.22.3862 · Cited by 136
Self-citationMultifaceted resistance of gliomas to temozolomide.
Bocangel, D., Finkelstein, S. D., Schold, S. C., Bhakat, K. K., MITRA, S. P., & Kokkinakis, D. M. (2002) · PubMed · Cited by 135
Paganelli, G., Bartolomei, M., Ferrari, M. E., Cremonesi, M., Broggi, G., Maira, G., Sturiale, C. L., Grana, C. M., Prisco, G., Gatti, M., et al. (2001) · Cancer Biotherapy and Radiopharmaceuticals · doi:10.1089/10849780152389410 · Cited by 131
Raffel, C., Frederick, L. A., O'Fallon, J. R., Atherton-Skaff, P., Perry, A., Jenkins, R. B., & James, C. D. (1999) · PubMed · Cited by 130
Tumor antigens in astrocytic gliomas
Kurpad, S. N., Zhao., X. ‐., Wikstrand, C. J., Batra, S. K., McLendon, R. E., & Bigner, D. D. (1995) · Glia · doi:10.1002/glia.440150306 · Cited by 120
Self-citationThe hypoxic tumor microenvironment and gene expression
Leo, C., Giaccia, A. J., & Denko, N. C. (2004) · Seminars in Radiation Oncology · doi:10.1016/j.semradonc.2004.04.007 · Cited by 119
Grombacher, T., MITRA, S. P., & Kaina, B. (1996) · Carcinogenesis · doi:10.1093/carcin/17.11.2329 · Cited by 119
O6-methylguanine-DNA methyltransferase in human normal and tumor tissue from brain, lung, and ovary.
Citron, M. L., Decker, R., Chen, S., Schneider, S., Graver, M. L., Kleynerman, L., Kahn, L. B., White, A., Schoenhaus, M., & Yarosh, D. B. (1991) · PubMed · Cited by 112
Wick, W., Wick, A., Schulz, J. B., DICHGANS, J., Rodemann, H. P., & Weller, M. (2002) · PubMed · Cited by 110
EGF receptor amplification and expression in human brain tumours
Chaffanet, M., Chauvin, C., Lainé, M. G., Berger, F. R., Chedin, M., Rost, N., Nissou, M.-F., & Benabid, A. L. (1992) · European Journal of Cancer · doi:10.1016/0959-8049(92)90374-b · Cited by 104
Olivi, A., Grossman, S. A., Tatter, S. B., Barker, F. G., Judy, K. D., Olsen, J. R., Bruce, J. N., Hilt, D. C., Fisher, J. D., & Piantadosi, S. (2003) · Journal of Clinical Oncology · doi:10.1200/jco.2003.09.041 · Cited by 103
Chang, S. M., Kuhn, J. G., Wen, P. Y., Greenberg, H. S., Schiff, D., Conrad, C. A., Fink, K., Robins, H. I., Cloughesy, T. F., DeAngelis, L. M., et al. (2004) · Investigational New Drugs · doi:10.1023/b:drug.0000036685.72140.03 · Cited by 97
Lin, H., Bondy, M. L., Langford, L. A., Hess, K. R., Delclos, G. L., Wu, X., Chan, W., Pershouse, M. A., Yung, W. K. A., & Steck, P. A. (1998) · PubMed · Cited by 93
Brooks, D. J., Beaney, R. P., Lammertsma, A. A., Leenders, K. L., Horlock, P. L., Kensett, M. J., Marshall, J., Thomas, D. G. T., & Jones, T. (1984) · Journal of Cerebral Blood Flow & Metabolism · doi:10.1038/jcbfm.1984.78 · Cited by 91
Parney, I. F., Kunwar, S., McDermott, M., Berger, M. S., Prados, M. D., Cha, S., Croteau, D. J., Puri, R. K., & Chang, S. M. (2005) · Journal of neurosurgery · doi:10.3171/jns.2005.102.2.0267 · Cited by 91
Tenascin expression in human glioma cell lines and normal tissues
Ventimiglia, J. B., Wikstrand, C. J., Ostrowski, L. E., Bourdon, M. A., Lightner, V. A., & Bigner, D. D. (1992) · Journal of Neuroimmunology · doi:10.1016/0165-5728(92)90029-k · Cited by 90
Self-citationIncidences of Gliomas and Meningiomas in Denmark, 1943 to 1997
Christensen, H. C., Kosteljanetz, M., & Johansen, C. (2003) · Neurosurgery · doi:10.1227/01.neu.0000064802.46759.53 · Cited by 89
Nagane, M., Narita, Y., Mishima, K., Levitzki, A., Burgess, A. W., Cavenee, W. K., & Huang, H. (2001) · Journal of neurosurgery · doi:10.3171/jns.2001.95.3.0472 · Cited by 83
Incidence of p14ARF gene deletion in high-grade adult and pediatric astrocytomas
Newcomb, E. W., Alonso, M., Sung, T., & Miller, D. C. (2000) · Human Pathology · doi:10.1016/s0046-8177(00)80207-5 · Cited by 82
Gururangan, S., Cokgor, I., Rich, J. N., Edwards, S., Affronti, M. L., Quinn, J. A., Herndon, J. E., Provenzale, J. M., McLendon, R. E., Tourt-Uhlig, S., et al. (2001) · Neuro-Oncology · doi:10.1093/neuonc/3.4.246 · Cited by 82
Self-citationIncreased teniposide clearance with concomitant anticonvulsant therapy.
Baker, D. K., Relling, M. V., Pui, C., et al. (1992) · Journal of Clinical Oncology · doi:10.1200/jco.1992.10.2.311 · Cited by 81
EGFR tyrosine kinase domain mutations in human gliomas
Marie, Y., Carpentier, A. F., Omuro, A. M. P., Sanson, M., Thillet, J., Hoang‐Xuan, K., & Delattre, J. (2005) · Neurology · doi:10.1212/01.wnl.0000158654.07080.b0 · Cited by 79
Silber, J. R., Blank, A., Bobola, M. S., Mueller, B. A., Kolstoe, D. D., Ojemann, G. A., & Berger, M. S. (1996) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.93.14.6941 · Cited by 79
Schmidt, E., Ichimura, K., Messerle, K. R., Goike, H., & Collins, V. P. (1997) · British Journal of Cancer · doi:10.1038/bjc.1997.2 · Cited by 77
Fan, Q.-W., Specht, K. M., Zhang, C., Goldenberg, D. D., Shokat, K. M., & Weiss, W. A. (2003) · PubMed · Cited by 76
Bartolomei, M., Mazzetta, C., Handkiewicz-Junak, D., Bodei, L., Rocca, P. A., Grana, C. M., Maira, G., Sturiale, C. L., Villa, G., & Paganelli, G. (2004) · PubMed · Cited by 73
EGFRMutations and Sensitivity to Gefitinib
Rossi, G., Marchioni, A., & Longo, L. (2004) · New England Journal of Medicine · doi:10.1056/nejm200409163511221 · Cited by 72
HOTTA, T., Saito, Y., Fujita, H., Mikami, T., Kurisu, K., Kiya, K., Uozumi, T., Isowa, G., Ishizaki, K., & Ikenaga, M. (1994) · Journal of Neuro-Oncology · doi:10.1007/bf01052897 · Cited by 70
Cloughesy, T. F., Kuhn, J. G., Robins, H. I., Abrey, L. E., Wen, P. Y., Fink, K., Lieberman, F. S., Mehta, M. P., Chang, S. M., Yung, A. W. K., et al. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.10.068 · Cited by 64
Growth factor profiles of human gliomas
van der Valk, P., Lindeman, J., & Kamphorst, W. (1997) · Annals of Oncology · doi:10.1023/a:1008265905505 · Cited by 56
Quantitative Aspects of Contrast Enhancement in Cranial Computed Tomography
Norman, D. M., Stevens, E. A., Wing, S. D., et al. (1978) · Radiology · doi:10.1148/129.3.683 · Cited by 55
Sampson, J. H., Reardon, D. A., Friedman, A. H., Friedman, H. S., Coleman, R. E., McLendon, R. E., Pastan, I. H., & Bigner, D. D. (2005) · Neuro-Oncology · doi:10.1215/s1152851703000589 · Cited by 54
Self-citationRainov, N. G., & Heidecke, V. (2004) · Journal of Neuro-Oncology · doi:10.1023/b:neon.0000013478.27604.01 · Cited by 51
Targeted radiotherapy of brain tumours
Zalutsky, M. R. (2004) · British Journal of Cancer · doi:10.1038/sj.bjc.6601771 · Cited by 50
Monoclonal antibodies for brain tumour treatment
Boskovitz, A., Wikstrand, C. J., Kuan, C., Zalutsky, M. R., Reardon, D. A., & Bigner, D. D. (2004) · Expert Opinion on Biological Therapy · doi:10.1517/14712598.4.9.1453 · Cited by 44
Self-citationWasserfallen, J., Ostermann, S., Pica, A., Mirimanoff, R., Leyvraz, S., Villemure, J., & Stupp, R. (2004) · Cancer · doi:10.1002/cncr.20619 · Cited by 35
(2003) · PubMed
Cited by
Clement, V., Sanchez, P., de Tribolet, N., Radovanovic, I., & Ruiz i Altaba, A. (2007) · Current Biology · doi:10.1016/j.cub.2006.11.033 · Cited by 1,050
Fan, X., Khaki, L., Zhu, T. S., Soules, M. E., Talsma, C. E., Gul, N., Koh, C., Zhang, J., Li, Y.-M., Maciaczyk, J., et al. (2010) · Stem Cells · doi:10.1002/stem.254 · Cited by 651
Diffuse glioma growth: a guerilla war
Claes, A., Idema, A. J., & Wesseling, P. (2007) · Acta Neuropathologica · doi:10.1007/s00401-007-0293-7 · Cited by 636
Glioblastoma multiforme: a review of where we have been and where we are going
Adamson, C., Kanu, O. O., Mehta, A. I., Di, C., Lin, N., Mattox, A. K., & Bigner, D. D. (2009) · Expert Opinion on Investigational Drugs · doi:10.1517/13543780903052764 · Cited by 550
Self-citationZhu, T. S., Costello, M. A., Talsma, C. E., Flack, C. G., Crowley, J. G., Hamm, L. L., He, X., Hervey-Jumper, S. L., Heth, J. A., Muraszko, K. M., et al. (2011) · Cancer Research · doi:10.1158/0008-5472.can-10-4269 · Cited by 400
Metadata
- Authors
- Reardon, D. A., Rich, J. N., Friedman, H. S., & Bigner, D. D.
- Venue
- Journal of Clinical Oncology
- Published
- 2006-03-10
- Volume
- 24
- Issue
- 8
- Pages
- 1253-1265
- ISSN
- 0732-183X (ISSN-L)
- 1527-7755
- OpenAlex
- W2142412446
- Cited by
- 307
- References
- 190
- FWCI
- 15.30
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.